Navigation Links
Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Date:10/16/2007

atment of high surgical-risk patients with

carotid artery disease. The Company plans to issue a press release at

this time.

-- Analyst Meeting. At 5:30 p.m., the Company will host an analyst

meeting in the Grand Ballroom of the Renaissance Hotel. The meeting is

open to the media and will include a DES clinical program update by Dr.

Donald Baim and a DES business update by Paul LaViolette. This meeting

is being webcast and can be accessed in the Investor Relations section

of Boston Scientific's website, http://www.bostonscientific.com. Please visit

the website for details on how to register for the webcast or to access

a replay, which will be archived for 90 days.

-- Symposium on Drug-Eluting Stents. From 8:00 - 10:00 p.m., the Company

will host a symposium entitled "Preclinical to Patients: The DES

Pathway" chaired by Keith D. Dawkins, M.D., in the Grand Ballroom of

the Renaissance Hotel. The symposium will include presentations on

drug development and actions of current DES molecules by Aloke V. Finn,

M.D.; the state of the DES market by Dr. Dawkins; late-breaking data on

next-generation DES by Dr. Turco; and impact of dual anti-platelet

therapy on DES outcomes by Steven R. Steinhubl, M.D. A reception will

be held prior to the symposium at 7:00 p.m.

The Company will also release additional safety and efficacy data from its comprehensive DES clinical trial program, which will be presented at TCT as e- posters. Details can be found on the official TCT program.

Boston Scientific will present its latest innovations and live case broadcasts at booth 3021 in the Exhibition Hall. Key product demonstrations will include drug-eluting stents, carotid artery stenting and peripheral interventions. In addition, Boston Scientific will i
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Inspire Announces Presentations at Two European Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... specializing in the development, manufacturing, and marketing of branded ... annual general meeting of shareholders (the "Meeting") will be ... Beijing time. The meeting will be held at No.699-18, ...
... /PRNewswire-iReach/ -- Global Information Inc. is pleased to ... Therapy market: Global Protein Therapeutics Market ... become one of the most effective clinical methods to ... metabolic disorders. While worldwide healthcare spending has decline in the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015 2
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive ... Healthcare Research and Policy Analysis show widespread support for the U.S. Affordable Care ... or strongly agreed that the controversial law passed in 2010 had “more good ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The U.S. ... under the chin. Kybella is similar to deoxycholic acid, which occurs naturally in the ... the main options to treat this area of the body. These are invasive procedures ...
(Date:8/3/2015)... ... 03, 2015 , ... Illinois Health & Science (IHS) has completed the purchase ... includes all of IBAM NA’s cyclotron sites and research and development facilities. ... business, as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ), ... treatments, will hold its quarterly conference call of its 2009 ... 11:30 AM Eastern Time. If you would like to participate, ... that day. The telephone replay will be available one hour ...
... , TAMPA, Fla., July 23 Bay Area ... chemical drugs and armed himself with a movie to help ... preventable illness, Burton found an alarming connection between America,s food ... Now he,s going to tell the world what he found. ...
... what a tale my thoughts could tell" Gordon Lightfoot ... and some new businesses, are banking on a brain imaging ... hidden thoughts, such as lies, truths or deep desires. ... Rutgers University provides evidence that fMRI can be used in ...
... risen over recent years. This is fact, but what is ... health centres have shown that family conflict is not a ... Primaria are striking: in Spain, 24% of women take antidepressants ... of psychopharmaceuticals is often related to family or work-related problems. ...
... , PRINCETON, N.J., July 23 The National ... several member associations today urged President Obama and members of Congress to ... most pervasive and costly diseases, a priority in reforming the U.S. healthcare ... to the President and lawmakers, NCDP said a national response to diabetes ...
... , BATESVILLE, Ind., July 23 Hill-Rom Holdings, Inc.,s, ... be issued Thursday, August 6, 2009. You are invited to participate ... a.m. EDT. , Earnings Release: Hill-Rom Holdings, ... 2009 will be released to the public after the NYSE close on ...
Cached Medicine News:Health News:Palomar Medical Technologies To Host Second Quarter 2009 Financial Results Conference Call and Webcast on July 30, 2009 2Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Can brain scans read your mind? 2Health News:Can brain scans read your mind? 3Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2
This portable resource provides definitions for medical acronyms and abbreviations....
Stedman's Medical Dictionary includes charts and tables and navigation and search tools....
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
Medicine Products: